Unlocking the Secrets of Antibody-Drug Conjugates: Inside the World of Antibody Internalization

Antibody-drug conjugates (ADCs) mainly consist of monoclonal antibodies, linkers, and cytotoxic payloads. The antibody, acting as the “missile” in ADC drugs, possesses target-specific functionality. It can selectively recognize tumor cell surface antigens, undergo internalization upon binding to these antigens, and deliver the cytotoxic payload to tumor cells to exert its toxic effects. Since not all […]

Advances in TROP2-ADC Drug Research

Tumor-Associated Calcium Signal Transducer 2 (TROP2), also known as TACSTD2 and EGP-1, is a surface antigen found in numerous solid tumors. It has become a pivotal target for pharmaceutical giants spurring a race in drug development in the world. Currently, TROP2-targeting biopharmaceuticals are predominantly concentrated in the Antibody-Drug Conjugate (ADC). Based on incomplete statistics, there are 11 TROP2-targeting […]

MMAE – The Beloved Toxin of ADCs

Antibody-drug conjugates (ADCs) represent a promising class of targeted therapies in the fight against cancer. These innovative therapies aim to deliver small-molecule chemotherapy agents directly to cancer cells while sparing healthy ones. Since the approval of MYLOTARG in 2000, ADCs have become a vital category in the realm of cancer-targeted treatments, consisting of three key […]